SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000947871-17-000387
Filing Date
2017-05-19
Accepted
2017-05-19 12:15:16
Documents
2
Group Members
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss43588_sc13d.htm SC 13D 98111
2 JOINT FILING AGREEMENT ss43588_ex99a.htm EX-99.A 13334
  Complete submission text file 0000947871-17-000387.txt   113174
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Subject) CIK: 0001404281 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88334 | Film No.: 17857024
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Filed by) CIK: 0001569821 (see all company filings)

IRS No.: 980697985 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D